Keyword results: Optibiotix Health

PREMIUM CONTENT

OptiBiotix Health – “in line” trading update, but now time for profitable delivery...

OptiBiotix Health (OPTI) has issued a trading update commenting that 2021 “total invoiced sales for the group were £2.2m (2020: £1.5m) an increase of 46.7% on the previous year and in line with market expectations” and including that it “has made good progress against its stated aims of focusing on a smaller number of large partners in key strategic markets and expects to see the benefits of these in 2022 and beyond”. What does that mean at the bottom-line?

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

OptiBiotix Health and SkinBioTherapeutics – further progress & triggers for dramatic 2022 re-rate

OptiBiotix Health (OPTI) was one of our tips of the year, with we anticipating financial progress as its deals for its compounds expand and further deals kick-in. It has now announced that a further human volunteer study on its cholesterol-reducing probiotic LPLDL - on a different population group of hypercholesterolemic adults – has shown “at six weeks, when volunteers taking placebo were compared to those taking LPLDL, there were statistically significant changes to clinically important cardiovascular risk”, including “34.2% reduction in total cholesterol (p=0.001)”.

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

OptiBiotix Health – further partner agreements positives...

OptiBiotix Health (OPTI) has followed a sales agreement with Apollo Hospitals Enterprises for its GoFigure weight management product range in India with an agreement for GoFigure and SlimBiome Medical in Saudi Arabia (KSA). Is this further encouraging progress or just more flannel?

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

OptiBiotix Health – launch of sports nutrition products to add £1m a year to sales, Buy

OptiBiotix Health (OPTI) has announced the launch of a new sports nutrition product range, LeanBiome, with a supply & licensing agreement with “a leading global player in beauty & nutrition”. What of a current share price response up to 42.5p?

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

OptiBiotix Health – shares nudge ahead on interims, much more to come

Life sciences compounds developer OptiBiotix Health (OPTI) has announced results for the first of calendar 2021, emphasising “sales of LPLDL and SlimBiome of £1.076m, a 44.5% increase over H1:2020… pleasing given the continued uncertain global economic environment and challenges of the subsequent waves of COVID-19, particularly in countries like India and the USA. The shares have currently responded slightly higher, to 50p.

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

OptiBiotix Health – extends Seed Health territories, strong buy

OptiBiotix Health (OPTI) has announced further growth with an agreement to extend the territories of its deal with Seed Health.

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

OptiBiotix Health – shares up on ‘trading and commercial update’, much further to go

OptiBiotix Health (OPTI) has made a “Trading and commercial update” including that sales are ahead of its expectations for the first six months of the year and that it “believes it is in a strong position to meet or exceed its full year sales forecast”. The shares have currently responded up to 49.5p but there looks much further to go.

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

OptiBiotix Health – strong commercial progress & company chat: this will be inflexion year: buy

OptiBiotix Health (OPTI) has announced a “Commercial strategy update” which shows strong progress in its strategy to initially build sales and brand presence and then move up the value chain by selling more product than ingredients and commercialising further compounds. We’ve also had a catch up chat with CEO Steve O’Hara. This should be THE YEAR when profits come close to or exceed £1 million.

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

OptiBiotix Health – trading update and company chat, Buy

OptiBiotix Health (OPTI) has announced a trading update, emphasising “another year of progress… probiotic and functional fibre divisions achieving profitability”. The shares have though currently responded lower to 55.5p, so what’s the current situation here? We’ve spoken to Chief Executive Steve O’Hara and we believe that Mr Market has got this one wrong.

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

OptiBiotix – Australia & New Zealand OptiBiome products launch, Asia to follow?...

OptiBiotix Health (OPTI“announces the launch of meal replacement shakes and bars containing OptiBiotix’s OptiBiome® proprietary weight management technology under the Optislim® brand with Woolworths, Chemist Warehouse and on OptiPharm Pty Ltd’s online store in Australia and New Zealand”…

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

OptiBiotix Health – another agreement with UITC, this time for CholBiomeX3...

OptiBiotix Health (OPTI) is “pleased to have signed an agreement with UITC to distribute CholBiomeX3 in Singapore”…

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

OptiBiotix – further expands SlimBiome Medical geographical reach, still a strong buy...

OptiBiotix (OPTI) has announced that it is “pleased to have signed an agreement with UITC to distribute our award-winning medical device in Singapore”…

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

OptiBiotix – LPLDL & CholBiome distributor agreement, strong buy...

OptiBiotix Health (OPTI) is “pleased to announce… an exclusive distribution agreement with Ayalla Marketing for the distribution of its cholesterol reducing probiotic, LPLDL®, as an ingredient and as four finished products (CholBiome, CholBiomeX3, CholBiomeBP and CholBiomeVH) within the CholBiome® portfolio for Brazil”

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

OptiBiotix – WellBiome distribution agreements, patience still required but still a strong buy...

OptiBiotix Health (OPTI) has recently been “pleased to announce the extension of terms for CTCThis agreement recognises CTC's success in building sales of SlimBiome® and extends terms to enhance further sales growth, supported by minimum sales targets. This is a first commercial step in bringing our new functional ingredient WellBiome® to global markets and building brand awareness” and pleased to announce… a second commercial step in bringing OptiBiotix's new functional ingredient WellBiome® to global markets and building brand awareness”...

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

OptiBiotix – clarifications and updates on more news from the company

More news from OptiBiotix Health (OPTI) and we’re also asked to clarify re. previous statements by the company...

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

OptiBiotix – shares down on historic numbers but look at the trading trajectory now...

Currently compounds to tackle obesity, high cholesterol and diabetes developer, OptiBiotix Health (OPTI) has announced results for the 13 months to 31st December 2019 (having moved its year-end from November), emphasising it “has met a significant number of important objectives that continue to build value for shareholders”. The shares have currently responded a bit lower to 62p, but the numbers are historic and look at the trading trajectory now...

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

OptiBiotix – sales trajectory sparks shares, but still an even stronger buy...

OptiBiotix Health (OPTI) has updated including noting first quarter of 2020 sales of £407,844 – and the shares have responded 11% higher to above 60p. Capitalising the company at around £53 million, why you may ask? Well, look at the company’s trajectory...

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

OptiBiotix – now Taiwan agreement adds to confidence...

OptiBiotix Health (OPTI) has announced it’s “pleased to have signed an agreement… to commercialise our award-winning weight management technology in Taiwan”

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

OptiBiotix – license agreement; potentially very exciting, Strong Buy...

OptiBiotix Health (OPTI) has announced “a non-exclusive license agreement for its SlimBiome® trademark with Smart For Life, Inc. and related launch of cookies containing OptiBiotix's SlimBiome® proprietary weight management technology in the USA and Canada”...

Subscribe to ShareProphets to access Premium Content

ShareProphets readers tips for 2020 competition – end April update

Having asked for readers tips for 2020 for the prize of 1/2 litre of Tom Winnifrith's Greek Hovel olive oil (2020 harvest) HERE, the following is an update on performance at the end of April (to be eligible needed to have selected, on a per username basis, a buy & sell pick from the LSE or AIM casino and the stocks not to have been suspended at the commencement of 2020)...

PREMIUM CONTENT

OptiBiotix – new agreements suggest shares remain a strong buy...

OptiBiotix Health (OPTI) has followed an “Exclusive licence agreement for OptiBiome®” with a contract manufacturing agreement for SlimBiome® with Fipros A/S, emphasising “the agreement is key”

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

OptiBiotix – “Change of accounting year end”… but this one clearly sensible…

Change of accounting year end” announcement from OptiBiotix Health (OPTI). But isn’t that a move of fraudsters or incompetents? Not in this case…

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

OptiBiotix – modified and extended agreement RNS emphasises attractiveness & share price fall

I have communicated with Steve O Hara. The share price of Optibiotix (OPTI) is 34p and that is freaking some folks out. The share price does not reflect what is going on. I think a formal trading statement would be useful.

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

OptiBiotix – developments to further support commercialisation

OptiBiotix Health (OPTI) has updated on a number of developments CEO Steve O'Hara emphasises “support the commercialisation of its ingredients and products”

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

OptiBiotix – LPLDL South America RNS & breaking news from H&B UK, Strong Buy

OptiBiotix Health (OPTI) has announced “a significant milestone” in extension of the use of its LPLDL probiotic strain into functional foods and its presence into South America. So what you say?...

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

OptiBiotix Health – first major retailer agreement (& look what’s set to follow…)

OptiBiotix Health (OPTI) has announced a first agreement with a major retailer for its SlimBiome® functional ingredient with a product range to be initially sold in the UK, Republic of Ireland, Netherlands, Belgium and Sweden by health food chain Holland & Barrett…

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

OptiBiotix Health – further medical device status & CE mark, further distribution agreements ahoy…

OptiBiotix Health (OPTI) is “very pleased to have been granted a medical device status and a CE mark for the second time over a 12-month period”...

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

OptiBiotix Health – further SkinBioTherapeutics shares sale reviewed

It has been announced OptiBiotix Health (OPTI) has sold 2.2 million further shares in 2017 spun-off onto AIM SkinBioTherapeutics (SBTX). This despite OptiBiotix’s results earlier this year including “SkinBiotherapeutics plc is making solid progress… As its partnership discussions turn into commercial agreements providing industry validation of its technology we anticipate SkinBiotherapeutics plc will grow in value, whereupon OptiBiotix shareholders will benefit from the appreciation of this asset”. So why the further sale?...

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

OptiBiotix Health – validations look to significantly increase LPLDL potential, remains a strong buy

OptiBiotix Health (OPTI) has updated investors with news including “completing Pharmaceutical GMP process validation and receiving the GRAS notification letter from the US FDA is a significant achievement for ProBiotix and LPLDL®. Few marketed probiotics have achieved this level of proven safety and efficacy and it has triggered another milestone payment in the US Pharmaceutical agreement”

Subscribe to ShareProphets to access Premium Content

OptiBiotix Health – another SlimBiome agreement, this time Australia and New Zealand…

OptiBiotix Health (OPTI) is pleased to announce an exclusive manufacturing, supply and distribution agreement for its SlimBiome weight management technology in Australia and New Zealand…

PREMIUM CONTENT

OptiBiotix Health – positive scientific and commercial update

An update from OptiBiotix Health (OPTI); “Scientific and commercial update”...

Subscribe to ShareProphets to access Premium Content

OptiBiotix – deal momentum continues: now Japan

OptiBiotix (OPTI) has announced another license agreement to we loyal shareholders. This one is for the use of its ProBiotix’s LPLDL ingredient in cardiovascular food supplements in Japan and is set to mean a first LPLDL finished product placement on the Japanese market…

PREMIUM CONTENT

OptiBiotix Health – license agreement momentum continues

More positive news from OptiBiotix Health (OPTI)?... The company has announced an exclusive license agreement for the commercialisation of, currently fully-owned subsidiary, ProBiotix's cholesterol management products CholBiome and CholBiomex3 in Vietnam…

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

Optibiotix – another week, another deal

Last week it was a Thai deal from OptiBiotix Health (OPTI), now there’s another for the European market...

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

Optibiotix – Indian manufacturing deal very good news, more to come

OptiBiotix Health (OPTI) has announced that it has entered into an exclusive manufacturing and supply agreement with Zeon Lifesciences. The agreement grants Zeon an exclusive license to manufacture and supply OptiBiotix's SlimBiome weight management technology in India, in return for 50% of the profit...

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

OptiBiotix Health - again a buy

Having reached circa 130p in August, shares in OptiBiotix Health (OPTI) have slid to 78p-81p. This is despite a pipeline of seemingly very significant deals likely to be converted and as such…

Subscribe to ShareProphets to access Premium Content
UKIS

2018 UK Investor Show ‘Dragon’s Den’ September update - Europa Metals takes top spot

The great success that was the 2018 UK Investor Show saw six 'Dragon's Den' sessions where a number of CEOs each gave a 1 minute (well, supposed to be!) pitch and three 'Dragons' at each session each picked a stock for a £1,000 investment. With the show having been on April 21st, here’s a monthly performance update...

UKIS

2018 UK Investor Show ‘Dragon’s Den’ monthly update - Tom continues to lead, Pizza Hardman off the bottom

The great success that was the 2018 UK Investor Show saw six 'Dragon's Den' sessions where a number of CEOs each gave a 1 minute (well, supposed to be!) pitch and three 'Dragons' at each session each picked a stock for a £1,000 investment. With the show having been in April, here’s a further monthly performance update...

UKIS

2018 UK Investor Show ‘Dragon’s Den’ - 1/3 way through, how's the standings?

The great success that was the 2018 UK Investor Show saw six 'Dragon's Den' sessions where a number of CEOs each gave a 1 minute (well, supposed to be!) pitch and three 'Dragons' at each session each picked a stock for a £1,000 investment. With the show having been on April 21st, how's the standings a third of the way through the competition?...

UKIS

2018 UK Investor Show ‘Dragon’s Den’ monthly update - soaring OptiBiotix boosts Tom's lead

The great success that was the 2018 UK Investor Show saw six 'Dragon's Den' sessions where a number of CEOs each gave a 1 minute (well, supposed to be!) pitch and three 'Dragons' at each session each picked a stock for a £1,000 investment. With the show having been in April, here’s a fourth performance update...

UKIS

2018 UK Investor Show ‘Dragon’s Den’ monthly update - Tom still the leader?

The great success that was the 2018 UK Investor Show saw six 'Dragon's Den' sessions where a number of CEOs each gave a 1 minute (well, supposed to be!) pitch and three 'Dragons' at each session each picked a stock for a £1,000 investment. With the show having been in April, here’s a third performance update...

2018 UK Investor Show ‘Dragon’s Den’ monthly update - does Tom remain the leader?

The great success that was the 2018 UK Investor Show saw six 'Dragon's Den' sessions where a number of CEOs each gave a 1 minute (well, supposed to be!) pitch and three 'Dragons' at each session each picked a stock for a £1,000 investment. With the show having been on April 21st, here’s a second performance update...

2018 UK Investor Show ‘Dragon’s Den’ update - who's the early leader?

The great success that was the 2018 UK Investor Show saw six 'Dragon's Den' sessions where a number of CEOs each gave a 1 minute (well, supposed to be!) pitch and three 'Dragons' at each session each picked a stock for a £1,000 investment. With the show having been on April 21st, here’s a first performance update...

OptiBiotix Health – another SlimBiome distribution agreement as momentum continues to build - STRONG BUY

OptiBiotix Health (OPTI) has added to recent newsflow aplenty with a distribution agreement for its SlimBiome weight management technology in the UK…

Optibiotix - funny old day, wait for the next news

OptiBiotix Health (OPTI) has announced the registration of five new microbial strains under the Budapest Treaty, increasing the number of registrations to eight, to protect the “recent advances” the company notes to have made.

Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Complete Coverage

Recent Comments

|